Related Experiment Videos
Hypofractionated radiotherapy for invasive bladder cancer
A N Scholten1, J W Leer, C D Collins
1Department of Clinical Oncology, University of Leiden, The Netherlands.
Summary
Hypofractionated radiotherapy for bladder cancer may lead to more late side effects, potentially negating benefits of fewer treatment sessions. This technique remains valuable for palliation and in resource-limited settings.
Area of Science:
- Oncology
- Radiation Oncology
- Urologic Oncology
Background:
- Historically, hypofractionated radiotherapy was used for invasive bladder cancer to reduce treatment sessions and conserve resources.
- This study compares outcomes of hypofractionation with conventional radiotherapy schedules.
Purpose of the Study:
- To evaluate the efficacy and toxicity of hypofractionated radiotherapy for invasive bladder cancer.
- To compare local control, survival, and morbidity rates with conventional radiotherapy.
Main Methods:
- Retrospective analysis of 123 patients with T2-T3 transitional cell carcinoma of the bladder treated between 1975 and 1985.
- Assessment of local control, survival, and complication rates following radical hypofractionated radiotherapy.
Main Results:
- Actuarial local control rates at 5 and 10 years were 31% and 29%, respectively.
- Cancer-specific survival rates at 5 and 10 years were 48% and 39%, respectively.
- While acute side effects were common (87%), late radiation side effects were more frequent compared to conventional schedules.
Conclusions:
- The reduction in treatment sessions with hypofractionated radiotherapy may be offset by increased long-term morbidity.
- Hypofractionation is a viable option for palliation and in situations with limited resources or equipment access.